The impact of Symprove™ multi-strain probiotic on enterotoxigenic Escherichia coli- or antibiotic-induced gut microbiome dysbiosis using high-throughput in vitro screening.

Symprove™ supplementation significantly increased SCFA levels (acetate, propionate, butyrate) compared to control in both healthy and dysbiosed populations.

• Acetate, propionate, and butyrate were all significantly increased with Symprove™ versus water control.
• These effects were observed across both healthy fecal microbiomes and dysbiosed microbiomes (antibiotic-induced and/or ETEC-infected).
• Measurements were taken at 24 h and 48 h timepoints using capillary gas chromatography.
• The study used a fractional factorial design with the Colon-on-a-plate® miniaturized short-term batch fermentation system.

Symprove™ supplementation significantly decreased levels of branched short-chain fatty acids (bSCFAs) compared to control in both healthy and dysbiosed populations.

• Branched SCFAs are considered markers of proteolytic fermentation, so their reduction is generally regarded as a favorable metabolic shift.
• The decrease in bSCFAs was observed in both healthy and dysbiosed (antibiotic-induced and ETEC) conditions.
• Effects were assessed at 24 h and 48 h using capillary gas chromatography.
• The fecal microbiome from 10 healthy human donors was used across all experimental conditions.

Symprove™ supplementation significantly altered several microbial metabolites beyond SCFAs, with many changes potentially beneficial for intestinal inflammation, intestinal barrier health, and the gut-brain axis.

• Untargeted metabolic fingerprinting and targeted metabolic profiling were used in addition to capillary gas chromatography to assess a broad range of microbial metabolites.
• Significant increases and decreases in several microbial metabolites were observed with Symprove™ compared to control.
• The paper reports these metabolite changes could be considered to have beneficial effects on intestinal inflammation, intestinal barrier health, and the gut-brain axis.
• These effects were demonstrated across healthy and multiple dysbiosed (low-, medium-, and high-dose antibiotic; ETEC) conditions.

Symprove™ demonstrated favorable metabolic impacts across different antibiotic doses (low, medium, and high) in the in vitro dysbiosis model.

• Three levels of antibiotic-induced dysbiosis (low-, medium-, and high-dose) were tested using the fractional factorial design.
• Favorable impacts on microbial metabolites were observed with Symprove™ supplementation across all antibiotic doses.
• Fecal microbiomes from 10 healthy human donors were used to generate the dysbiosed conditions.
• The Colon-on-a-plate® system was used as a miniaturized short-term batch fermentation platform for these assessments.

The study employed a Colon-on-a-plate® miniaturized short-term batch fermentation system with a fractional factorial design to evaluate probiotic effects on fecal microbiomes from 10 healthy human donors under multiple conditions.

• Conditions included healthy and dysbiosed states: enterotoxigenic Escherichia coli (ETEC) infection and/or low-, medium-, or high-dose antibiotics.
• Samples were supplemented with Symprove™ or water (control) and evaluated at 24 h and 48 h.
• Three analytical methods were applied: untargeted metabolic fingerprinting, capillary gas chromatography, and targeted metabolic profiling.
• The fractional factorial design allowed assessment of multiple dysbiosis conditions and Symprove™ supplementation effects simultaneously across 10 donors.